Honeybees exposure to veterinary drugs: how the gut microbiota is affected

Running title: Tylosin and Sulphonamides impact honeybees microbiota.

L. Baffoni¹, D. Alberoni^{1*}, F. Gaggia¹, C. Braglia¹, C. Stanton^{2,3}, P.R. Ross^{2,3}, D. Di Gioia¹

¹Department of Agricultural and Food Sciences (DISTAL), University of Bologna, Viale Fanin 44, 40127 Bologna, Italy

²Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.

³APC Microbiome Institute, University College Cork, Co. Cork, Ireland

Corresponding author: Daniele Alberoni

daniele.alberoni@unibo.it

+39 3201175257

Abstract

Several studies have outlined that a balanced gut microbiota offers metabolic and protective functions supporting honeybee health and performances. The present work contributes to increasing knowledge on the impact on the honeybee gut microbiota of the administration of three different veterinary drugs (oxytetracycline, sulphonamides and tylosin). The trial was designed with a semi-field approach in micro-hives containing about 500 bees, i.e. in experimental conditions as close as possible to real hives considering the restrictions on the use of antibiotics; 6 replicates were considered for each treatment plus the control. The absolute abundance of the major gut microbial taxa in newly eclosed individuals was studied with qPCR and next generation sequencing. Antimicrobial resistance genes for the target antibiotics were also monitored using a qPCR approach. The results showed that none of the veterinary drugs altered the total amount of gut bacteria, but qualitative variations were observed. Tylosin treatment determined a significant decrease of α - and β -diversity indexes and a strong the depletion of the rectum population (lactobacilli and bifidobacteria) while favoring the hindgut population (*Gilliamella*, *Snodgrassella* and *Frischella* spp.). Major changes were also observed in honeybees treated with sulphonamides, with a decrease in *Bartonella* and *Frischella* core taxa an increase of *Bombilactobacillus* spp. and *Snodgrassella* spp. Conversely, minor effects were observed in oxytetracycline treated honeybees. Monitoring of antibiotic resistance genes confirmed that honeybees represent a great reservoir of tetracycline resistance genes. Tetracycline and sulphonamides resistant genes tended to increase in the gut microbiota population upon antibiotic administration.

Importance

This study investigates the impact of the three most widely used antibiotics in the beekeeping sector (oxytetracycline, tylosin and sulphonamides) on the honeybee gut microbiota and on the spread of

antibiotic resistance genes. The research represents an advancement to the present literature considering that tylosin and sulphonamides effect on the gut microbiota has never been studied. Another original aspect lies in the experimental approach used, as the study looks at the impact of veterinary drugs and feed supplements 24 days after the beginning of the administration, thus exploring perturbations in newly eclosed honeybees, instead of the same treated honeybee generation. Moreover, the study is not performed with cage tests but in micro-hives thus reaching conditions closer to real hives. The study reaches the conclusion that tylosin and sulfonamides determine major changes in some core members and that antibiotic resistance genes for tetracycline and sulphonamides increase upon antibiotic treatment.

Introduction

Bees have a globally recognized importance for the maintenance of the planet biodiversity and crops pollination (1, 2). In addition, honeybees are valuable for the production of commercially important hive products, such as honey, propolis, royal jelly and wax.

In the last 150 years, farming practices aimed at increasing livestock productivity have been applied and antibiotics have played a crucial role (3) in intensive breeding. Honeybees are not an exception and large-scale apiaries of dozens of beehives have replaced the few hives in the yard of farmers and wild colonies (4). Moreover, hives are often moved for long distances for agriculture pollination needs (5; 6) or shipped worldwide for transnational commercialization (7, 8).

The intensive exploitation of agricultural systems and pollinators resources (9) contribute to honeybee stress in such a way that they can no longer survive without constant anthropogenic inputs (10, 11). Among the biotic and abiotic factors that are affecting honeybee health, pathogens and parasites play the greatest role. These, acting in synergy with abiotic factors, have caused significant decline in the European colonies (12, 13).

In order to fight microbial pathogens, several antibiotics are used, such as oxytetracycline-HCl

(Terramycin[®]) against *Paenibacillus larvae* (14), tylosine (Tylovet[®]) against *Melissococcus plutonius* (15, 16), and sulphonamides to control both pathogenic bacteria and, partially, Nosemosis, caused by *Nosema apis* and *Nosema ceranae* (16). The virulence and spread of pathogens are often enhanced by modern beekeeping practices (17), like the unnatural proximity of colonies (18) and frames exchange (19).

Since the early 2000s, concern about the spread of antibiotic resistance genes among pathogenic bacteria has led many nations to apply restrictions on their use on livestock (20, 21). In apiculture, most of the authorizations to trade certain antibiotics have been withdrawn by the European Commission or by pharmaceutical companies themselves (22, 23). Conversely, antibiotic administration to honeybees is permitted, in many other countries, even though with restriction and controls (24, 25), and the European honey market is still threatened by antibiotic residues (26).

The honeybee gut microbiota is relatively simple, composed of few core bacterial genera and other non-core genera with a low or occasional presence (27, 28). Commensal gut bacteria, besides their role in honeybee nutrition and physiology, act in synergy with the host immune system and play a role in modulating the insect response to pathogens (29, 30). The honeybee gut microbiota is directly influenced by various factors such as diet, season and exposure to chemical compounds such as weed killers or antibiotics (31- 33) and its unbalance, defined as intestinal dysbiosis (34), may negatively influence honeybee well-being.

In this work, we investigated the effect on the honeybee gut microbial community of the most used veterinary drugs such as oxytetracycline, sulphonamides and tylosin. A number of studies, often based on cage tests or on hybrid approach between cage test and restricted realise time into the hive, have considered the impact of oxytetracycline on the honeybee gut microbiota, whereas, to the best of our knowledge, sulphonamides and tylosin have never been investigated before. This study has been performed using a semi field approach, *e.g.* in experimental conditions as close as possible to real hives taking into account the restrictions on the use of antibiotics, thus partially avoiding artificial

conditions typical of the cage tests. Perturbation of the gut microbiota in newly eclosed individuals are explored with the use of qPCR and next generation sequencing (NGS) and antimicrobial resistance genes for the target antibiotics were monitored.

Results

General observations on the colonies status pre and post treatment

The trial involved bees treated with tetracycline (PT), sulphonamides (SUL) and tylosin (TL), plus an untreated control (CTR); each experimental condition was tested with 6 replicates. Bees were sampled at T0 (experiment beginning) and T1 (24 days later). Samples are therefore expressed as sampling time – experimental condition – replicate number (e.g.: T0_CTR_1). Moreover, the experiment relied on micro-hives managed with a semi-field approach due to national restriction.

The health status of the treated honeybee micro-hives was generally good all over the trial. Only one micro-hive collapsed (PT_6) just after the experiment end, presumably due to varroosis, whereas CTR_5, PT_1 and SUL_1 were found to be queenless during the experiment. Visual evaluation at the time of gut sampling highlighted a reddish coloration of the intestinal epithelium in the tylosin treatment group. Drought conditions in the second half of the experiment did not allow nectar harvest.

qPCR quantification of total bacteria, *Bifidobacterium* and Lactobacillaceae in the gut

The count of Eubacteria (Fig. 1A) at the beginning and at the end of the experiment showed a significant decrease (0.65 Log, $p < 0.05$) upon sulphonamide treatment (SUL_T0 vs SUL_T1); the other treatment did not show significant variation. A non-significant decreased was observed in the control micro-hives (CTR_T0 vs CTR_T1) with a loss of 0.21 Log 16S rRNA copies/intestine. *Bifidobacterium* spp. counts showed a general decrease in all experimental conditions. The reduction was significant in PT_T0 vs PT_T1 (0.58 Log CFU/intestine, $p < 0.01$) and in TL_T0 vs TL_T1 (3.61

Log CFU/intestine decrease, $p < 0.01$; Fig. 1B). Also, Lactobacillaceae showed a general decrease in all experimental conditions, which was significant only in the comparison of TL_T0 vs TL_T1 ($p < 0.01$) with a decrease of 0.56 Log CFU/intestine (Fig. 1C).

Bee Gut microbiota analysis via NGS

A total of 48 samples [2 sampling times, T0 and T1, 4 experimental conditions (CTR, PT, SUL, TL), 6 replicates for each condition, each replicate being a pool of 30 honeybee guts] were subjected to NGS analysis on Illumina MiSeq platform. About 13.7 million raw reads were obtained from the sequencing. 9.1 million reads passed the quality control and the Chimera check analysis obtaining an average of 95,986 joint reads per sample. For statistical analysis, samples were rarefied at 48,400 reads, a value obtained excluding one replicate (TL_T1_4) due to a particularly low coverage. The taxonomical assignment of the 47 samples produced 17,194 OTUs at 97% similarity based on SILVA 132 database. The elaboration of NGS data on the whole dataset is reported in Table 3, where absolute abundance at phyla, family and genus level are reported per treatment and time, whereas Fig. 2A reports absolute abundance at genus level per replicate.

Detected non-core genus could be mainly ascribed to the genera: *Asaia*, *Apibacter*, *Arsenophonus*, *Vagococcus*, *Pseudomonas*, *Parasaccharibacter*, *Citrobacter*, *Providencia* and *Pantoea* (Fig. 2B) and their proportion at T0 and T1 (Fig. 2C).

α -diversity indexes (Chao1, Observed OTU and PD whole tree) showed a significant decrease over time only in tylosin treated group ($p < 0.01$; Fig. S1). The analysis of β -diversity (Table S1) underlined statistically significant differences in the unweighted UniFrac analysis, which stresses the importance of taxa presence/absence, only comparing CTR to TL treatment. However, considering the abundance of taxa in the weighted UniFrac, not only TL treatment resulted significant but also SUL when compared to CTR (Table S1).

155 Antibiotic effect

156 Control bees did not show any significant shift of the intestinal microbial taxa at the different
157 taxonomic levels, comparing the two sampling times. A summary of the significant changes from
158 phyla to species for each antibiotic treatment between the two sampling times level is reported in
159 Table 2.

160 PT treatment, at phylum level, showed an increase of Firmicutes (from 40.9% at T0 to 47.5% at T1)
161 and a decrease of Proteobacteria (from 52.2% to 45.6%), although not significant, whereas
162 Actinobacteria remained stable. At family level, comparing PT_T1 vs PT_T0, Bartonellaceae showed
163 a decreasing trend but not significant (from 8.66% to 7.27%), while both Neisseriaceae and Orbaceae
164 significantly increased from 3.94% to 7.31% ($p<0.01$) and from 18.5% to 26.7% ($p<0.05$),
165 respectively. At genus level, *Gilliamella* spp. almost doubled its absolute abundance comparing
166 PT_T1 vs PT_T0 (from 14.07% to 20.84%; $p<0.05$), while *Snodgrassella* significantly increased
167 (from 4.03 to 7.36; $p=0.01$; Fig. 3D). At species level, PT treatment determined a significant increase
168 only for *Lactobacillus kullabergensis* ($p<0.01$).

169 Tetracycline resistance gene *tetB* increased significantly of 159% ($p<0.01$) comparing PT_T1 vs
170 PT_T0. However, the increase was also significant comparing CTR_T1 vs CTR_T0 ($p<0.01$). Also,
171 *tetY* drastically increased comparing PT_T1 vs PT_T0 ($p<0.01$) whereas CTR did not show any
172 significant changes.

173 Regarding SUL treatment, at phylum level, Firmicutes showed a significant increase comparing
174 SUL_T1 vs SUL_T0, from 34.1% to 55.2% ($p<0.05$). On the contrary, Proteobacteria decreased
175 significantly from 59.5% to 38.8% ($p<0.05$). Actinobacteria slightly decreased from 6.31% at T0 to
176 5.97% at T1 although not significantly. At family level, Bartonellaceae decreased after treatment
177 (from 39.66% to 5.45%; $p<0.01$) (Fig. 3C), while Neisseriaceae and Acetobacteraceae significantly
178 increased from 3.21% and 0.67% at T0 to 6.07% and 5.60% at T1, respectively ($p<0.05$).

179 At genus level, SUL treatment at T1 determined a significant decrease in the absolute abundance of

180 *Bartonella* spp. reflecting the proportions reported at family level ($p < 0.01$; Fig. 3A), and *Frischella*
181 spp. (from 3.20% to 0.98% $p < 0.05$; Fig. 3E). On the other hand, absolute abundance increased in
182 *Bombilactobacillus* spp. (from 6.13% to 15.74%; $p < 0.01$; Fig. 3C), *Gilliamella* spp. (from 11.18% to
183 19.56%; $p < 0.05$; Fig. 3F), *Snodgrassella* spp. (from 3.19% to 6.10%; $p < 0.05$; Fig. 3H) and
184 Other_genus ($p < 0.05$; Fig. 3I). At species level, a significant increase was reported for *A. kunkeei*
185 ($p > 0.05$), *Bombilactobacillus mellifer* ($p < 0.01$) and *Bombilactobacillus mellis* ($p < 0.01$). *Bartonella*
186 *apis*, *Frischella perrara* and *Gilliamella apicola* reflected the genus trend, being the only species
187 within the respective genus.

188 Sulphonamides resistance gene *sul1* and *sul2* showed a significant increase of 76.84% and 33.95%,
189 respectively, comparing SUL_T1 vs SUL_T0 ($p < 0.01$) respectively, whereas *sul3* did not produce
190 any amplification at the different annealing temperatures tested (40, 44, 48, 52, 56, 60 and 64 °C).

191 Proteobacteria doubled their abundance comparing TL_T1 vs TL_T0, from 42.3% at T0 to 87.4% at
192 T1 ($p < 0.01$). On the other hand, both Firmicutes and Actinobacteria significantly decreased from
193 48.5% to 12.6% ($p < 0.01$) and from 9.19% to 0.024% ($p < 0.01$), respectively. Bifidobacteriaceae and
194 Lactobacillaceae significantly decreased between TL_T1 and TL_T0 ($p < 0.01$) with percentage values
195 that are consistent with those reported below at the genus level. Orbaceae significantly increased
196 from 16.9% at T0 to 28.5% at T1 (+68.63%, $p < 0.01$). Finally, absolute abundance of Other_families
197 significantly increased after TL treatment, from 1.18% at T0 to 7.15% at T1 (+673%, $p < 0.01$).

198 *Bifidobacterium* spp. absolute abundance reduction after TL treatment was highly significant
199 ($P < 0.01$), decreasing from 9.32% at T0 to 0.02% at T1 (Fig. 3B). In the same way,
200 *Bombilactobacillus* spp. and *Lactobacillus* spp. decreased from 10.61% and 37.52% at T0 to 0.81%
201 and 9.37% at T1 ($p < 0.01$; Fig. 3C and 3G), respectively. Moreover, *Bartonella* spp. doubled the
202 absolute abundance (from 19.18% to 40.96%; $p < 0.05$; Fig. 3A) together with *Gilliamella* spp. and
203 Other_genus in TL_T1, that significantly increased from 14.16% and 1.84% at T0 to 24.90% and
204 12.40% at T1, respectively ($p < 0.01$; Fig. 3F and 3I). At species level, a significant decrease of six

Lactobacillus species and also of unclassified *Lactobacillus* spp. was observed ($p < 0.01$), together with the decrease of *B. mellis* ($p < 0.01$), *B. asteroides* ($p < 0.01$) and *B. indicum* ($p < 0.05$). The Cramer V test showed a strong biological relevance in pairwise comparisons of TL_T1 vs TL_T0 and SUL_T1 vs SUL_T0 (Cramer V = 0.53 and 0.45 respectively) (35). PT_T1 vs PT_T0 and CTR_T1 vs CTR_T0 biological relevance was moderate (Cramer V = 0.25 and 0.23) but not negligible. Tylosin resistance gene *tlrB* and *tlrD* did not showed any significant variation in normalized data. PCA analysis of the dataset at species level PC1 and PC2 together explain only 25% of the variability. However, TL_T1 group is clearly separated from TL_T0 and also from the other treated samples at T1 (Fig. 4A), particularly along the PC1. Orbaceae and thus *Gilliamella* spp. are associated with TL_T1 as also confirmed by statistical analysis (Fig. 4B and 4C). The graph also shows a clear separation of SUL_T0 and T1 along PC2.

Discussion

This work investigates the gut microbial community of honeybees, which have not been treated with antibiotics for several generations after the supplementation of antibiotics (oxytetracycline, sulphonamides and tylosin).

The observed decrease of total bacterial in treated and control bees could not be ascribed to the antibiotic treatment, but, rather, it seemed to be related with the bee physiology, or stress due to the limited freedom. However, the antibiotic exposure significantly influenced some gut microbial groups.

Oxytetracycline is a broad-spectrum antibiotic currently used in the beekeeping sector (24, 36). Recently, Raymann *et al.* (31, 37) showed that the use of tetracycline strongly decreased the absolute abundance of 5 gut core genera in partially caged honeybees, with a significant decrease of *Bartonella*, *Bifidobacterium*, *Bombilactobacillus* spp. (formerly known as *Lactobacillus* Firm-4),

Lactobacillus and *Snodgrassella*. Our findings suggest a possible resilience mechanism to the disturbance imposed by oxytetracycline since variations were observed only in two core members (*Bartonella* and *Snodgrassella*) and no significant changes were found in the studied diversity indexes. It is ascertaining that honeybee gut commensal bacteria provide large reservoirs of tetracycline resistance determinants (*otr* and *tet* genes) frequently acquired through massive and/or long-term antibiotic exposure or from other ecosystems shared with animals and humans (38, 39). Ludvigsen et al. (39) showed that honeybee gut symbionts, in particular *Snodgrassella* spp. and *Gilliamella* spp., can survive and proliferate thanks to *tet* determinants. Recently, Daisley et al. (40) found that the routine administration of oxytetracycline increases *tetB* and *tetY* abundance in the gut microbiota of adult workers associated with a depletion of the major symbiont taxa. The present study therefore confirms that honeybees represent an impressive reservoir of tetracycline resistance genes, even after two decades without antibiotic treatment. As already mentioned, our experiments were performed on the new honeybee generation, differently from other studies that targeted bees of the same generation (37-38; 40). Beside antibiotic resistant genes uptake, bees, with their daily activities (hive interaction, flying, flower visiting), have a preferred path to replenish their gut microbiota. Most of the published studies rely on caged or partially caged honeybees, which limits social behavior, interactions with the environment but also honeybees queen and brood pheromones for social regulation and interactions. In addition, our work was performed in micro-hives and, therefore, the reservoir of microbial inoculants present in the hive structure (stored pollen, nectar and wax foundation) may have contributed to the mitigation of tetracycline impact.

Sulphonamides (SUL) have been widely used in the beekeeping sector from 1960 to 2000, but residues in honey are still found, thus showing that they are still used in spite of the banning (41). Among the core genera found in the honeybee gut, *Frischella* and *Bartonella* spp. were significantly affected by SUL treatment, while *Bombilactobacillus* spp. and *Snodgrassella* spp. increased their counts. *Frischella perrara* has implications in immune priming in honeybees and in the induction of

peptides with antimicrobial activity (42). The registered 3% reduction (with a final 1% abundance in T1) could be detrimental for the bee defense mechanisms. *Bartonella* spp. has been related to the recycling of nitrogenous waste products into amino acids and with the degradation of secondary plant metabolites. The reduction of more than 80% of this taxon could have implication in digestion functions and in the recovery of amino acids (43). However, it is evident that most of the core members are not affected by SUL treatment. This can be again a consequence of the uptake of sulphonamides resistance genes, that was confirmed with both gene *sul1* and *sul2* in this research. This is coherent with results recently obtained by Cenci-Goga *et al.* (44) that found sulphonamide resistance genes (*sul1* and *sul2*) in a large number of honeybees sampled in different Italian locations. Tylosin induced a remarkable change in some microbial taxa proportion, almost causing the depletion of the rectum population (lactobacilli and bifidobacteria) and favoring the hindgut population (mostly *Gilliamella*, but also *Snodgrassella* and *Frischella*). It is known that tylosin targets are mainly Gram-positive bacteria (45; 46). Both *Bifidobacterium*, *Bombilactobacillus* and *Lactobacillus* genera represented 99.99% of Bifidobacteriaceae and Lactobacillaceae family members that, overall, accounted for more than a half of the honeybee gut microbial community. They play an essential role in the transformation of various pollen coat-derived compounds, including flavonoids, phenolamides and ω -hydroxy acids (47), in addition to the complex sugars' breakdown (48, 49). Their rapid decrease may affect honeybee ability to metabolize specific compounds and consequently reduce nutrient availability. It is remarkable that macrolide antibiotic resistance genes *tlrB* and *tlrD* did not increase significantly in treated honeybees at T1, even if detected. This is probably due to the low occurrence of these antibiotic resistance genes (ARG) in *Bombilactobacillus*, *Lactobacillus* and *Bifidobacterium* honeybee strains, even if TL resistant strains are described in humans and swine (50, 51). *Tlr* genes belong to the same resistance group of *erm* genes (erythromycin ribosome methylation), so that *tlrB* is also classified as *erm32* whereas *tlrD* as *ermN* (52, 53). The presence of *tlr* genes and the lack of decrease upon TL treatment may also be explained by their activity against

other macrolide antibiotics that have a broader spectrum of activity, including Gram-negative bacteria that survived the TL treatment. Jackson et al. (54) found that erm genes can be activated after tylosin use. Vice versa *tlr* genes might confer resistance to some macrolide in tylosin unsensitive Gram-negative bacteria populating the honeybee gut thus explaining their presence at T0 and T1. Several studies showed that environmental species, such as members of the *Asaia*, *Apibacter*, *Apilactobacillus*, *Vagococcus*, *Pseudomonas*, *Parasaccharibacter*, *Citrobacter*, *Providencia* and *Pantoea* genera, often related with soil, pollen and nectar (55, 56), are detected in the honeybee gut as minor groups (57-59). These non-core genera were found to increase at T1 upon treatments with SUL and TL. These microorganisms may increase the pool of ARG, due to their continuous exposure to antibiotics used in agroecosystem (e.g.: sewage from livestock distributed on soil). For instance, *Parasaccharibacter apium*, recently reclassified as *Bombella* sp. by Smith et al., (60), is reported as a strong immune stimulating strain in honeybees, also capable of counteracting *Nosema* sp. (61). The non-core genera that are sporadically associated with honeybees might play a role in the immune stimulation or metabolic regulation of honeybees, despite their low abundance. Interestingly, the limited interaction with the environment did not prevent their acquisition as gut commensal bacteria over the experimental time.

Overall, the three assayed veterinary drugs do not impact quantitatively the gut bacterial community in terms of total amount of bacteria, but they influence the absolute abundance of several core taxa, causing a possible lack of metabolic functions related to the most susceptible bacterial species and strains. A long-term observation of the colony health status, also including the hive development and hive products (e.g. honey), will allow the understanding of the relationship between the altered microbial structure and the behaviour and performance of honeybees.

Experimental Procedure

Experimental design

Due to the European and national law restricting the use of antibiotics or other veterinary drugs as antimicrobial in open field, these were tested in semi-field conditions, i.e. in micro-hives incubated in a thermostatic chamber

with a limited flying time for honeybees. Honeybees employed in this study have not been treated with antibiotics for several generations (over two decades).

The micro-hives employed in the study were obtained as depicted in Fig. 6A. Shook swarming of a fully populated and healthy bee hive was used to populate 72 micro-combs (L 9.5 x H 10.5 cm). The queen was allowed laying eggs for three days on approximately 1/3 of the total available micro-combs. 5 days later, 24 experimental wooden micro hives (L 20 x H 15 x W 16 cm) were set up, each containing 3 micro-combs (a brood frame, a honey frame and an empty comb). Each micro hive contained approximately 500 honeybees with a mated queen. The obtained micro-hives constituted the experimental replicates (6 for each experimental condition). Moreover, every micro hive was equipped with an anti-robbing entrance modification, forcing honeybees to walk a “S” path that discouraged the entrance of robber bees when the micro hives were placed outside.

Micro-hives were located into an incubator with controlled temperature and humidity (29°C and 60 RH), and well equipped with a net allowing ventilation on the mini-hive bottom. The micro-hives were moved outside in the late afternoon (approx. from 5.30 pm to 8.30 pm) every second day in order to allow the bees to fly freely and defecate. The arrangement of the micro hives outdoor in the experimental field always followed the same pattern to avoid disorientation and drift. Micro hives were placed at minimum 2 m distance from each other, and in clusters of 3 units of the same experimental thesis, oriented in different directions, in an experimental forest well populated by trees.

At early night-time, micro-hives were closed and re-allocated in the lab thermostat. Micro hives were

fed every two days with a 30 ml 1:1 (w:w) sucrose solution, plus a 5 ml sterile water dispenser. The day of the antimicrobial treatment, honeybees were treated as described below. The developed experimental conditions were: [TL] tylosin, [PT] oxytetracycline, [SUL] a mixture of sulfaquinoxaline and sulfadimethoxine, and the control with no antibiotic administration [CTR]. Details on antibiotics use and concentration are reported below.

The trial was carried out between July and August, 2016, where two foraging options were available: *Metcalfa pruinosa* honeydew in the early august and *Medicago sativa* blooming all along the trial even if strongly limited by summer drought. The health status (adult honeybee population and brood size, honey reserves, core colony cohesion, symptoms of viral diseases and varroa infestation) of honeybee micro hives was periodically assessed, and variations annotated when relevant.

Treatment preparation, administration and sampling

Antibiotics were administered according to available guideline for each antibiotic (62-64). Details and concentrations of antibiotics are reported in Table 1. Bees were treated once a week for three weeks with micro hive feeders containing 30 mL of sugar syrup (1:1 w/w) mixed with the respective treatment. Finally, in the days after the 3rd treatment (days 15-17), at least 50 emerging honeybees per replicate were marked on the thorax (65) with coloured nail polish non-toxic to bees. Marked honeybees were sacrificed at day 24, at nurse stage (7-9 days post eclosure) and with a completely established gut microbiota (66). A pool of 30 bees per replicate (a total of 180 samples/experimental condition) was picked at the beginning of the experiment (T0) and after 24 days (T1).

DNA extraction and NGS sequencing

Obtained honeybee gut pools were well homogenised with pestles, with addition of 1400 µl lysis solution improved with 60 µl proteinase K per pool (20 mg/ml concentration), and glass beads until

total destruction of gut epithelial tissues after 1-hour incubation at 55°C. Only 1/4 of the resulting sludge (450 µl) was used for gut genomic DNA extraction with Quick-DNA Fecal and Soil Microbe Kit (Zymo Research, California, U.S.A). The 16S rRNA gene amplification and libraries preparation for Illumina MiSeq platform sequencing were carried out according to Alberoni et al., (67). Bioinformatic analyses were performed with Qiime1, and representative OTUs blasted against the most updated SILVA database release 132. The database was implemented inserting full length 16S rRNA sequences of administered beneficial bacteria. OTUs with less than 0.1% abundance were discarded. α -diversity was evaluated using Chao1, Observed OTU and PD whole tree metrics, whereas β -diversity was evaluated using both weighted and unweighted UniFrac.

Quantification of target microbial groups and resistance genes

Total bacteria (Eubacteria), Lactobacillaceae family, *Lactobacillus* spp., *Bombilactobacillus* spp. and *Bifidobacterium* spp. were quantified with qPCR (StepOne™ Real-Time PCR System, Applied Biosystems) according to Baffoni et al., (68-69). Data for Lactobacillaceae (*Apilactobacillus* spp., *Bombilactobacillus* spp., *Lactobacillus* spp. and *Lactoplantibacillus* spp.) and *Bifidobacterium* spp. were transformed to obtain the number of microorganism as Log CFU/single intestinal content (70, 71). For total bacteria data were expressed as Log 16S rRNA copies/intestine (72). ARG genes *TetB*, *TetY*, *Sul1*, *Sul2*, *Sul3*, *TlrB* and *TlrD* were quantified according Zhang et al. (73) . Primers used are reported in Table 4. Raw data were corrected according to the total DNA quantification. The final absolute abundance of ARG was normalized according to (82, 83) by dividing the total ARG with the absolute abundance of total bacteria previously obtained, data reported show the ratio between ARG and total bacteria.

Data adjustments and classification of microbial genera

Rarefied biom tables obtained from NGS bioinformatic analysis were used for further data adjustments: the absolute abundance of each bacteria species was calculated according to [Raymann et al., \(31\)](#), by multiplying absolute abundance data to the corresponding qPCR total amount results, and normalizing by the copy number of 16S rRNA gene typical of each microbial genus. Moreover, species belonging to the *Lactobacillus* genus have been recently re-classified ([84](#)) but databases for NGS OTUs assignment were not yet updated with the new classification at the time of the bioinformatic analysis of the presented data. Therefore, the absolute abundance dataset was manually curated to assign the former *Lactobacillus* spp. Firm-4 to *Bombilactobacillus* spp. genus and the former *Lactobacillus kunkeei* and *Lactobacillus plantarum* to the new respective taxonomical classifications *Apilactobacillus kunkeei* and *Lactoplantibacillus plantarum*. Due to the sequencing amplicon length (≈ 470 bp) might not be enough to efficiently discriminate among species, the manual curation was then validated in qPCR with Firm-4 and Firm-5 specific primers ([33](#)). The obtained dataset was used for further graphical and statistical analyses on target genera and species.

Statistical analysis

Statistical analysis for qPCR and NGS data (α -diversity and taxon analysis) was performed with the R software ([85](#)) according to [Baffoni et al. \(68\)](#). Analysis on data normality and homoscedasticity was performed, therefore normal and homoscedastic data were analysed with ANOVA, non-normal, homoscedastic data (with normal distribution of residuals) were analysed with glm function, data with high deviation from normality were analysed with non-parametric Kruskal-Wallis test coupled with Dunn-test. For β -diversity index, data resulting from QIIME statistical elaboration were reported. The software calculates the UniFrac distance (weighted and unweighted UniFrac) between all the pairs of samples in the dataset to create a distance matrix. The statistical significance between

groups was subsequently estimated using the Monte Carlo method with the Bonferroni correction. Post-hoc test among different groups was carried out and Bonferroni's correction was applied. The post-hoc test considered pairwise comparisons within each experimental condition, taking into consideration the impact of each treatment over time. Therefore, four comparisons for the semi-field trial and three comparisons for the *in-field* trial were considered. The control was considered as a further treatment to monitor and evaluate the normal gut microbial community evolution resulting from the interaction of honeybees with the environment. Graphs were generated with ggplot2, ggpubr and Microsoft Excel. Biological relevance of experimental conditions, pairwise compared at their respective sampling time (T1 vs T0) was computed with Cramér's V (86) relying on packages rcompanion, vcd, psych, desctools and epitools. Finally, PCA analysis was performed using packages FactoMineR (87) and factoextra (88), taking into consideration 71 taxa at species level.

Data availability

These sequence data have been submitted to NCBI repository under the Sequence Read Archive (SRA) databases under accession numbers SAMN16442373-SAMN16442378; SAMN16442391-SAMN16442396; SAMN16442397-SAMN16442402; SAMN16442409-SAMN16442414; SAMN16442427-SAMN16442432; SAMN16442444-SAMN16442449; SAMN16442450-SAMN16442455 and SAMN16442462-SAMN16442467, Bio project n° PRJNA669646. Supplementary data, including excel files of elaborated data obtained from qPCR for target microbial groups and ARG and NGS data categorized at phyla, family and genera level, can be found at the Dryad Digital Repository (DOI.....).

Compliance with ethical standards

This article does not contain any studies with human participants by any of the authors and experiments on animals were performed according to the Italian laws that allows experiments on arthropods without the need of an official ethical commission approval, unless cephalopods are used.

Acknowledgments

The research was partially funded by the EU project “NOurishingPROBiotics to bees to Mitigate Stressors” (NO PROBLEMS), H2020-MSCA-RISE 2017, GA 77760, 2018-2022. The founder had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

Competing interests: The authors declare no competing interests.

References

1. Faheem M, Aslam M, Razaq M. 2004. Pollination ecology with special reference to insects a review. J Res Sci 4:395-409.
2. Ollerton J, Winfree R, Tarrant S. 2011. How many flowering plants are pollinated by animals? Oikos 120:321-326.
3. Laxminarayan R, Van Boeckel T, Teillant A. 2015. The economic costs of withdrawing antimicrobial growth promoters from the livestock sector. OECD Food Agri Fish 78.
4. Daberkow S, Korb P, Hoff F. 2009 Structure of the US beekeeping industry: 1982–2002. J Econ Entomol 102: 868-886.

5. Kellar BM. 2018. Honey bees and apple trees: Hood River Oregon as a case study for the creation of the honey bee pollination industry. Oregon State University Archive, OR.
6. Sáez A, Aizen MA, Medici S, Viel M, Villalobos E, Negri P. 2020. Bees increase crop yield in an alleged pollinator-independent almond variety. Sci Rep 10:1-7.
7. Shimanuki H, Knox DA. 1997. Bee health and international trade. Revue scientifique et technique-Office international des epizooties 16:172-182.
8. Zammit-Mangion M, Meixner M, Mifsud D, Sammut S, Camilleri L. 2017. Thorough morphological and genetic evidence confirm the existence of the endemic honey bee of the Maltese Islands *Apis mellifera ruttneri*: recommendations for conservation. J Apicult Res 56:514-522.
9. Aizen MA, Harder LD. 2009. The global stock of domesticated honey bees is growing slower than agricultural demand for pollination. Curr Biol 19:915-918.
10. Fontana P, Costa C, Di Prisco G, Ruzzier E, Annoscia D, Battisti A, Caoduro G, Carpana C, Contessi A, Dal Lago A, Dall'Olio R, De Cristofaro A, Felicioli A, Floris I, Fontanesi L, Gardi T, Lodesani M, Malagnini V, Manias L, Manino A, Marzi G, Massa B, Mutinelli F, Nazzi F, Pennacchio F, Porporato M, Stoppa G, Tormen T, Valentini M, Segrè A. 2018. Appeal for biodiversity protection of native honey bee subspecies of *Apis mellifera* in Italy San Michele all'Adige declaration. Bul Insectology 71:257-271.
11. Requier F, Garnery L, Kohl PL, Njovu HK, Pirk CWW, Crewe RM, Steffan-Dewenter I. 2019. The conservation of native honey bees is crucial. Trends Ecol Evolut 34:789-798.

12. Moritz RF, Erler S. 2016. Lost colonies found in a data mine: global honey trade but not pests or pesticides as a major cause of regional honeybee colony declines. *Agr Ecosyst Environ* 216:44-50.
13. Maini S, Medrzycki P, Porrini C. 2010. The puzzle of honey bee losses: a brief review. *Bull Insectol* 63:153-160.
14. Genersch E. 2010. American Foulbrood in honeybees and its causative agent *Paenibacillus larvae*. *J Invertebr Pathol* 103:10-19.
15. Hitchcock JD, Moffett JO, Lockett JJ, Elliott JR. 1970. Tylosin for control of American foulbrood disease in honey bees. *J Econ Entomol* 63:204-207.
16. Reybroeck W, Daeseleire E, De Brabander HF, Herman L. 2012. Antimicrobials in beekeeping, *Vet Microbiol* 158:1-11.
17. Gordon R, Bresolin-Schott N, East IJ. 2014. Nomadic beekeeper movements create the potential for widespread disease in the honeybee industry. *Aust Vet J* 92:283-290.
18. Nolan MP, Delaplane KS. 2017. Distance between honey bee *Apis mellifera* colonies regulates populations of *Varroa destructor* at a landscape scale. *Apidologie* 48:8-16.
19. Zanet S, Battisti E, Alciati R, Trisciuglio A, Cauda C, Ferroglio E. 2019. *Nosema ceranae* contamination in bee keeping material: the use of ozone as disinfection method. *J Apicult Res* 58:62-66.

20. Tang KL, Caffrey NP, Nóbrega DB, Cork SC, Ronksley PE, Barkema HW, Polachek AJ, Ganshorn H, Sharma N, Kellner JD, Ghali WA. 2017. Restriction in the use of antibiotics in food animals and antibiotic resistance in food animals and humans—a systematic review and meta-analysis. University of Calgary, Canada. In: WHO guidelines on use of medically important antimicrobials in food-producing animals, WHO. <https://www.ncbi.nlm.nih.gov/books/NBK487956/>
21. World Health Organization. 2017. WHO guidelines on use of medically important antimicrobials in food-producing animals: web annex A: evidence base. No. WHO/NMH/FOS/FZD/17.2.
22. Commission Regulation EU. 2010. No, 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin, with honey bee *Apis mellifera* Foragers. Off J Eur Union 15:1-72
23. Sneeringer S, Bowman M, Clancy M. 2019. The US and EU Animal Pharmaceutical Industries in the Age of Antibiotic Resistance. No. 1477-2019-2172.
24. Underwood R, Traver BE, López-Urbe MM. 2019. Beekeeping management practices are associated with operation size and beekeepers' philosophy towards in-hive chemicals. Insects 10:10.
25. Cilia L. 2019. The plight of the honeybee: a socioecological analysis of large-scale beekeeping in the United States. Sociol Ruralis 59:831-849.
26. Reybroeck W. 2018., Residues of antibiotics and chemotherapeutics in honey. J Apicult Res 57:97-112.

27. Kwong WK, Moran NA. 2016. Gut microbial communities of social bees. *Nature Rev Microbiol* 14:374.
28. Praet J, Aerts M, De Brandt E, Meeus I, Smagghe G, Vandamme P. 2016. *Apibacter mensalis* sp. nov.: a rare member of the bumblebee gut microbiota. *Int J Syst Evol Microbiol* 66:1645-1651.
29. Kwong WK, Mancenido AL, Moran NA. 2017. Immune system stimulation by the native gut microbiota of honey bees. *R Soc O Sci* 4:170003.
30. Raymann K, Moran NA. 2018. The role of the gut microbiome in health and disease of adult honey bee workers. *Curr Opin Insect Sci* 26:97-104.
31. Raymann K, Shaffer Z, Moran NA. 2017. Antibiotic exposure perturbs the gut microbiota and elevates mortality in honeybees. *PLoS Biology* 15:e2001861.
32. Motta EV, Raymann K, Moran NA. 2018. Glyphosate perturbs the gut microbiota of honey bees. *PNAS* 115:10305-10310.
33. Kešnerová L, Emery O, Troilo M, Liberti J, Erkosar B, Engel P. 2020. Gut microbiota structure differs between honeybees in winter and summer. *ISME J* 14:801-814.
34. Sartor RB. 2008. Therapeutic correction of bacterial dysbiosis discovered by molecular techniques. *PNAS* 105:16413-16414.

35. Kotrlík JW, Williams HA, Jabor MK. 2011. Reporting and Interpreting Effect Size in Quantitative Agricultural Education Research. *J Agr Edu* 52:132-142.
36. Steinhauer N, Saegerman C. 2020. Prioritizing changes in management practices associated with reduced winter honeybee colony losses for US beekeepers. *Sci Total Environ* 753:141629.
37. Raymann K, Bobay LM, Moran NA. 2018. Antibiotics reduce genetic diversity of core species in the honeybee gut microbiome. *Mol Ecol* 27:2057-2066.
38. Tian B, Fadhil NH, Powell JE, Kwong WK, Moran NA. 2012. Long-term exposure to antibiotics has caused accumulation of resistance determinants in the gut microbiota of honeybees. *MBio* 3.
39. Ludvigsen J, Amdam GV, Rudi K, L'Abée-Lund TM. 2018. Detection and characterization of streptomycin resistance *strA-strB* in a honeybee gut symbiont *Snodgrassella alvi* and the associated risk of antibiotic resistance transfer. *Microb Ecol* 76:588-591.
40. Daisley BA, Pitek AP, Chmiel JA, Gibbons S, Chernyshova AM, Al KF, Faragalla KM, Burton JP, Thompson GJ, Reid G. 2020. *Lactobacillus* spp, attenuate antibiotic-induced immune and microbiota dysregulation in honey bees. *Comm Biol* 3:1-13.
41. Piva S, Giacometti F, Marti E, Massella E, Cabbri R, Galuppi R, Serranio A. 2020. Could honey bees signal the spread of antimicrobial resistance in the environment? *Lett Appl Microbiol* 70:349-355.

42. Emery O, Schmidt K, Engel P. 2017. Immune system stimulation by the gut symbiont *Frischella perrara* in the honey bee *Apis mellifera*. Mol Ecol 26:2576-2590.
43. Segers FH, Kešnerová L, Kosoy M, Engel P. 2017. Genomic changes associated with the evolutionary transition of an insect gut symbiont into a blood-borne pathogen. ISME J 11:1232-1244.
44. Cenci-Goga BT, Sechi P, Karama M, Ciavarella R, Pipistrelli MV, Goretti E, Elia AC, Gardi T, Pallottini M, Rossi R, Selvaggi R, Grispoldi L. 2020. Cross-sectional study to identify risk factors associated with the occurrence of antimicrobial resistance genes in honey bees (*Apis mellifera*) in Umbria Central Italy. Environ Sci Poll Res 1-9.
45. Westermarck E, Skrzypczak T, Harmoinen J, Steiner JM, Ruaux CG, Williams DA, Eerola E, Sundback P, Rinkinen M. 2005. Tylosin-responsive chronic diarrhea in dogs. J Vet Intern Med 19:177-186.
46. Yin F, Dong H, Zhang W, Zhu Z, Shang B, Wang Y. 2019. Removal of combined antibiotic (florfenicol tylosin and tilmicosin) during anaerobic digestion and their relative effect. Renew Energ 139:895-903.
47. Bonilla-Rosso G, Engel P. 2018. Functional roles and metabolic niches in the honey bee gut microbiota. Curr Opin Microbiol 43: 69-76.
48. Lee FJ, Rusch DB, Stewart FJ, Mattila HR, Newton IL. 2015. Saccharide breakdown and fermentation by the honey bee gut microbiome. Environ Microbiol 17:796–815.

49. Milani C, Turrone F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M. 2015. Genomics of the genus *Bifidobacterium* reveals species-specific adaptation to the glycanrich gut environment. *Appl Environ Microbiol* 82:980–991.
50. Whitehead TR, Cotta MA. 2001. Sequence analyses of a broad host-range plasmid containing *ermT* from a tylosin-resistant *Lactobacillus* sp. isolated from swine feces. *Curr microbiol* 43:17-20.
51. Luo C, Hang X, Liu X, Zhang M, Yang X, Yang H. 2015. Detection of *erm(X)*-mediated antibiotic resistance in *Bifidobacterium longum* subsp. *longum*. *Ann Microbiol* 65:1985-1991.
52. Maravic G. 2004. Macrolide resistance based on the *Erm*-mediated rRNA methylation. *Curr Drug Targ Inf Dis* 4:193-202.
53. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. 1999. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. *Antimic Ag Chemother* 43:2823-2830.
54. Jackson CR, Fedorka-Cray PJ, Barrett JB, Ladely SR. 2004. Effects of tylosin use on erythromycin resistance in enterococci isolated from swine. *Appl Environ Microbiol* 70:4205-4210.
55. Álvarez-Pérez S, Lievens B, Fukami T. 2019. Yeast–bacterium interactions: the next frontier in nectar research. *Trends Plant Sci* 24:393-401.
56. Liu H, Macdonald CA, Cook J, Anderson IC, Singh BK. 2019. An ecological loop: host microbiomes across multitrophic interactions. *Trends Ecol. Evol* 34:1118-1130.

618

619 57. Zhang W, Zhang X, Su Q, Tang M, Zheng H, Zhou X. 2020. Genomic features underlying the
620 evolutionary transitions of *Apibacter* to honey bee gut symbionts. bioRxiv
621 <https://doi.org/10.1101/2020.09.30.321786>

622

623 58. Ahn JH, Hong IP, Bok JI, Kim BY, Song J, Weon HY. 2012. Pyrosequencing analysis of the
624 bacterial communities in the guts of honey bees *Apis cerana* and *Apis mellifera* in Korea. J Microbiol
625 50:735-745.

626

627 59. Khan KA, Ansari MJ, Al-Ghamdi A, Nuru A, Harakeh S, Iqbal J. 2017. Investigation of gut
628 microbial communities associated with indigenous honey bee (*Apis mellifera jemenitica*) from two
629 different eco-regions of Saudi Arabia. Saudi J Biol Sci 24:1061-1068.

630

631 60. Smith EA, Anderson KE, Corby-Harris V, McFrederick QS, Newton IL. 2020. Reclassification
632 of seven honey bee symbiont strains as *Bombella apis*. BioRxiv
633 <https://doi.org/10.1101/2020.05.06.081802>

634

635 61. Corby-Harris V, Snyder L, Meador CAD, Naldo R, Mott B, Anderson KE. 2016.
636 *Parasaccharibacter apium* gen. nov. sp. nov. improves honey bee (Hymenoptera: Apidae) resistance
637 to Nosema. J Econ Entomol 109:537-543.

638 62. Skinner AA, Parkman JP, Studer MD. 2013. Using terramycin for the prevention of American
639 foulbrood. University of Tennessee, TN.

640

641 63. Mutinelli F. 2003. Practical application of antibacterial drugs for the control of honey bee
642 diseases. APIACTA 38:46-49.

643

644 64. Elzen PJ, Westervelt D, Causey D, Ellis J, Hepburn HR, Neumann P. 2002. Method of
645 application of tylosin an antibiotic for American foulbrood control with effects on small hive beetle
646 (Coleoptera: Nitidulidae) populations. J Econ Entomol 95:1119-1122.

647

648 65. De Smet L, Hatjina F, Ioannidis P, Hamamtzoglou A, Schoonvaere K, Francis F, Meeus I,
649 Smagghe G, de Graaf DC. 2017. Stress indicator gene expression profiles colony dynamics and
650 tissue development of honey bees exposed to sub-lethal doses of imidacloprid in laboratory and field
651 experiments. PloS one 12: e0171529.

652

653 66. Martinson VG, Moy J, Moran NA. 2012. Establishment of characteristic gut bacteria during
654 development of the honeybee worker. Appl Environ Microbiol 78:2830-2840.

655

656 67. Alberoni D, Favaro R, Baffoni L, Angeli S, Di Gioia D. 2021. Neonicotinoids in the
657 agroecosystem: in-field long-term assessment on honeybee colony strength and microbiome. Sci
658 Total Environ 762:144116.

659

660 68. Baffoni L, Gaggia F, Di Gioia D, Santini C, Mogna L, Biavati B. 2012. A *Bifidobacterium*-based
661 synbiotic product to reduce the transmission of *C. jejuni* along the poultry food chain. Int J Food
662 Microbiol 157:156-161.

663

664 69. Baffoni L, Gaggia F, Alberoni D, Cabbri R, Nanetti A, Biavati B, Di Gioia D . 2016. Effect of
665 dietary supplementation of *Bifidobacterium* and *Lactobacillus* strains in *Apis mellifera* L. against
666 *Nosema ceranae*. Benef Microbes 7:45-51.

667

70. Lee ZM, Bussema III C, Schmidt TM. 2009. rrnDB: documenting the number of rRNA and tRNA genes in bacteria and archaea. *Nucleic Acids Res* 37:D489-D493.
71. Stoddard SF, Smith BJ, Hein R, Roller BR, Schmidt TM. 2015. rrnDB: improved tools for interpreting rRNA gene abundance in bacteria and archaea and a new foundation for future development. *Nucleic Acids Res* 43:D593-D598.
72. Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. *Microbiol* 148:257-266.
73. Zhang Y, Wang J, Lu J, Wu J. 2020. Antibiotic resistance genes might serve as new indicators for wastewater contamination of coastal waters: Spatial distribution and source apportionment of antibiotic resistance genes in a coastal bay. *Ecol Indic* 114:106299.
74. Rinttilä T, Kassinen A, Malinen E, Krogus L, Palva A. 2004. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. *J Appl Microbiol* 97:1166–1177.
75. Castillo M, Martín-Orúe SM, Manzanilla EG, Badiola I, Martín M, Gasa J. 2006. Quantification of total bacteria enterobacteria and lactobacilli populations in pig digesta by real-time PCR. *Vet Microbiol* 114:165–170.
76. Muyzer G, DeWaal EC, Uitterlinden AG. 1993. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. *Appl Environ Microbiol* 59:695–700.

693

694 77. Koike S, Aminov RI, Yannarell AC, Gans HD, Krapac IG, Chee-Sanford JC, Mackie RI.. 2010.
695 Molecular ecology of macrolide–lincosamide–streptogramin B methylases in waste lagoons and
696 subsurface waters associated with swine production. Microb Ecol 59:487-498.

697

698 78. Kern MB, Klemmensen T, Frimodt-Møller N, Espersen F. 2002. Susceptibility of Danish
699 *Escherichia coli* strains isolated from urinary tract infections and bacteraemia and distribution of *sul*
700 genes conferring sulphonamide resistance. J Antimic Chemother 50:513-516.

701

702 79. Pei R, Kim SC, Carlson KH, Pruden A. 2006. Effect of river landscape on the sediment
703 concentrations of antibiotics and corresponding antibiotic resistance genes (ARG). Water
704 Res 40:2427-2435.

705

706 80. He X, Xu Y, Chen J, Ling J, Li Y, Huang L, Xie G. 2017. Evolution of corresponding resistance
707 genes in the water of fish tanks with multiple stresses of antibiotics and heavy metals. Water
708 Res124:39-48.

709

710 81. Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. 2014. Development of a prokaryotic
711 universal primer for simultaneous analysis of Bacteria and Archaea using next-generation
712 sequencing. PloS one 9:e105592.

713

714 82. McKinney CW, Dungan RS, Moore A, Leytem AB. 2018. Occurrence and abundance of
715 antibiotic resistance genes in agricultural soil receiving dairy manure. FEMS Microbiol
716 Ecol 94:fiy010.

717

83. Chen C, Li J, Chen P, Ding R, Zhang P, Li X. 2014. Occurrence of antibiotics and antibiotic resistances in soils from wastewater irrigation areas in Beijing and Tianjin China. *Environ Pollut* 193:94-101
84. Zheng J, Wittouck S, Salvetti E, Franz CM, Harris H, Mattarelli P, O'Toole PW, Pot B, Vandamme P, Walter J, Watanabe K, Wuyts S, Felis GE, Ganzle MG, Lebeer S. 2020. A taxonomic note on the genus *Lactobacillus*: description of 23 novel genera emended description of the genus *Lactobacillus* Beijerinck 1901 and union of Lactobacillaceae and Leuconostocaceae. *Int J Syst Evol Microbiol* 70:2782-2858.
85. R Core Team. 2020. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria. <https://www.R-project.org/>
86. Cohen J. 1988. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ: Laurence Erlbaum Associates.
87. Le S, Josse J, Husson F. 2008. FactoMineR: an R package for multivariate analysis. *J Stat Softw* 25:1-18.
88. Kassambara A, Mundt F. 2020. Factoextra: extract and visualize the results of multivariate data analyses. R package version 1.5, 1:337-354.

Tables legends

Table 1 Antibiotics used in this work, their dosages applied in each treatment per hive in the presented trials, and recommended doses for full size colonies. All antibiotics or antimicrobial agents were prepared in 30 mL of sugar syrup and sprayed on, or fed to bees. *Dose recalculated according to the colony size of microhives, expressed as mg or μ L of active ingredient dissolved in 30 mL of sugar syrup. **Total recommended dose for 3 administrations with weekly cadence;

Table 2 Significant variation among microbial groups at phyla, family, genus and species level according to the experimental conditions.

Table 3 NGS absolute abundance at phyla, family and genus level, reported per treatment and sampling time.

Table 4 List of primers used in this experiment to carry out quantification of specific microbial targets, and detection of ARGs.

Figure Legends

Fig. 1A-1C qPCR. quantification of (A) total bacteria (Eubacteria), (B) *Bifidobacterium* spp. and (C) *Lactobacillaceae*. Data are expressed in Log CFU/intestine for *Bifidobacterium* spp. and *Lactobacillaceae*; for Eubacteria data are expressed as Log 16S rRNA copies/intestine. Boxplots report minimum and maximum values, lower and upper quartile and median. **Antibiotics:** [CTR] Antibiotics Control, [PT] oxytetracycline, [SUL] sulphonamides, [TL] tylosin.

Fig. 2A-2C NGS Absolute Abundance overview. (A) bar charts reporting the major cumulated microbial genera per samples and their absolute abundance expressed in percentage. (B) pie-charts reporting the minor cumulated microbial genera (Other_taxa) per experimental conditions and sampling time, expressed in percentage as absolute abundance. (C) average absolute abundance of Other_taxa for each treatment in T0 and T1.

Fig. 3A-3F NGS Absolute Abundance at genus level. Box plots reporting the major microbial genera expressed for their absolute abundance in percentage, and in relation to experimental conditions (significant pairwise comparisons * $p < 0.05$; *** $p < 0.01$). Boxplots report minimum and maximum values, lower and upper quartile and median. **Microbial taxa described:** (A) *Bartonella* spp., (B) *Bifidobacterium* spp., (C) *Bombilactobacillus* spp., (D) *Commensalibacter* spp., (E) *Frischella* spp., (F) *Gilliamella* spp., (G) *Lactobacillus* spp., (H) *Snodgrassella* spp., (I) Other_genus, for the experimental conditions: [CTR] Control, [PT] oxytetracycline, [SUL] sulphonamides, [TL] tylosin.

Fig. 4A–4F PCA analysis. (A) PCA was performed with 71 taxa at species level, confidence ellipses are shown in the graphs. (B) The graph includes the top seven variables with the highest contrib. (C) The graph includes the variables with $\cos^2 > 0.6$.

Fig. 5A-5G Antibiotic resistance gene: Box plots reporting the AGRs for (A) *tetB*, (B) *tetY* for tetracycline resistance genes; (C) *sulI* and (D) *sul2* for sulphonamides resistance genes; (E) *tlrB* and (F) *tlrD* for tylosin resistance genes. The absolute AGR quantification is normalized with the total 16S rRNA gene copies, in relation to experimental conditions (significant pairwise comparisons * $p < 0.05$; *** $p < 0.01$).

Fig. 6 Experimental Design. The figure reports the scheme of the tests and the number of bees and

790 beehives used in the trials.

A Eubacteria

B *Bifidobacterium* spp.

C *Lactobacillaceae*

A **B** **C**

<i>Antibiotic / Chemotherapies</i>					
Experimental Theses			Dose per treatment *	Recommended doses for full size colonies	Reference article
Experimental	Active Ingredient	Commercial Brand			
PT	Oxytetracycline HCl	Pan-Terramicina [®] Zoetis	13.5 mg	800-1200 mg **	62-63
TL	Tylosin Tartrate	Tylan Soluble Elanco [™]	10.0 mg	200 mg/7g powdered sugar **	64
SUL	Sulfaquinoxaline 2% + Sulfadimethoxine 1%	Sulfac Formevet [®]	4.5 mg	1 g/3.7L**	63
CTR	-	-	-	-	-

	SUL	TL	PT	CTR
Phyla	Firmicutes ↑ Proteobacteria ↓	Actinobacteria ↓ Firmicutes ↓ Proteobacteria ↑	Firmicutes ↑	
Family	Acetobacteraceae ↑ Bartonellaceae ↓ Neisseriaceae ↑ Other_families ↑	Bifidobacteraceae ↓ Lactobacillaceae ↓ Orbaceae ↑ Other_families ↑	Neisseriaceae ↑ Orbaceae ↑	
Genus	<i>Bartonella</i> ↓ <i>Bombilactobacillus</i> ↑ <i>Frischella</i> ↓ <i>Gilliamella</i> ↑ <i>Snodgrassella</i> ↑ Other_genus ↑	<i>Bartonella</i> ↑ <i>Bifidobacterium</i> ↓ <i>Bombilactobacillus</i> ↓ <i>Gilliamella</i> ↑ <i>Lactobacillus</i> ↓ Other_genus ↑	<i>Gilliamella</i> ↑ <i>Snodgrassella</i> ↑	
Species	<i>A. kumkei</i> ↑ <i>Bartonella apis</i> ↓ <i>B._mellifer</i> ↑ <i>B._mellis</i> ↑ <i>Frischella perrara</i> ↓ <i>G. apicola</i> ↑ <i>S. alvi</i> ↑	<i>B. apis</i> ↑ <i>B. asteroides</i> ↓ <i>B. indicum</i> ↓ <i>B. mellis</i> ↓ <i>G. apicola</i> ↑ <i>L. apis</i> ↓ <i>L. helsinborgensis</i> ↓ <i>L. kimbladii</i> ↓ <i>L. kullabergensis</i> ↓ <i>L. melliventris</i> ↓	<i>L. kullabergensis</i> ↑	

Phyla

	T0_CTR	T1_CTR	T0_PT	T1_PT	T0_SUL	T1_SUL	T0_TL	T1_TL
Actinobacteria	7,23	7,27	6,87	6,90	6,32	5,97	9,20	0,02
Firmicutes	32,76	45,57	40,94	47,54	34,15	55,21	48,51	12,58
Proteobacteria	60,01	47,16	52,18	45,55	59,54	38,82	42,29	87,40

Family

	T0_CTR	T1_CTR	T0_PT	T1_PT	T0_SUL	T1_SUL	T0_TL	T1_TL
Bifidobacteriaceae	7,23	7,31	6,82	6,65	6,29	5,85	9,12	0,02
Lactobacillaceae	32,68	46,10	40,74	45,98	34,02	53,33	48,09	13,16
Bartonellaceae	36,12	17,46	26,87	8,86	39,66	5,45	19,18	40,02
Neisseriaceae	4,31	3,94	3,94	7,31	3,21	6,07	3,64	5,80
Acetobacteraceae	1,58	1,88	1,83	0,90	0,67	5,60	1,89	5,32
Orbaceae	15,73	18,68	18,52	26,88	14,46	20,37	16,91	28,53
Other_Families	2,36	4,64	1,30	3,44	1,69	3,33	1,18	7,15

Genera

	T0_CTR	T1_CTR	T0_PT	T1_PT	T0_SUL	T1_SUL	T0_TL	T1_TL
Bifidobacterium	7,23	7,33	6,85	6,64	6,33	5,93	9,32	0,02
Lactobacillus	26,94	33,75	32,49	38,57	27,82	37,78	37,52	9,37
Bombilactobacillus	5,03	11,72	8,66	7,27	6,13	15,74	10,61	0,81
Apilactobacillus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00
Plantilactobacillus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,03
Bartonella	36,44	17,44	26,65	8,91	39,70	5,67	19,18	40,96
Commensalibacter	0,53	0,38	0,80	0,68	1,17	0,43	0,86	1,47
Snodgrassella	4,32	3,98	4,03	7,36	3,19	6,10	3,65	5,93
Frischella	2,46	3,19	4,60	6,01	3,20	0,98	2,84	4,30
Gilliamella	13,30	15,43	14,07	20,84	11,18	19,56	14,16	24,72
Other_Genera	3,74	6,78	1,84	3,71	1,26	7,81	1,84	12,40

	Primer Name	Sequence (5'-3')	Amplicon size	Reference
Bifidobacteriaceae (qPCR)	Bif TOT-F	TCGCGTCYGGTGTGAAAG	243	74
	Bif TOT-R	CCACATCCAGCRTCCAC		
Lactobacillaceae (qPCR)	Lac-F	GCAGCAGTAGGGAATCTTCCA	364	75
	Lac-R	GCATTYCACCGCTACACATG		
Eubacteria (qPCR)	Eub338-F	ACTCCTACGGGAGGCAGCAG	200	76
	Eub518-R	ATTACCGCGCTGCTGG		
Tylosin resistance gene B	Tlr B-F	GTGTCCTGGAGGAGTTCGAG	111	77
	Tlr B-R	AGCGGAAGTGTGTCCCATAC		
Tylosin resistance gene D	Tlr D-F	GTCAACGACGACTTCACGAC	186	77
	Tlr D-R	ACTGGGCGTTGAAGAGATTG		
Sulphonamides resistance 1	Sul1-F	CGGCGTGGGCTACCTGAACG	433	78
	Sul1-R	GCCGATCGCGTGAAGTTCCG		
Sulphonamides resistance 2	Sul2-F	GCGCTCAAGGCAGATGGCATT	293	78
	Sul2-R	GCCTTTGATACCGGCACCCGT		
Sulphonamides resistance 3	Sul3-F	TCCGTTTCAGCGAATTGGTGCAG	/	79
	Sul3-R	TTCGTTTCAGCCTTACACCAGC		
Tetracycline resistance gene B	TetB-F	GGTTGAGACGCAATCGAATT	206	73
	TetB-R	AGGCTTGGAATACTGAGTGTA		
Tetracycline resistance gene Y	TetY-F	GCTGATATTTGCGGGTTTCTA	177	80
	TetY-R	CGTCAAGCCTGTAAAGTTCC		
Illumina adapter - V3-V4 Region of 16S rRNA gene	Pro341-F	AATGATACGGCGACCACCGAGATCT ACACTCTTTCCCTACACGACGCTCTT CCGATCTCCTACGGGAGGCAGCAG- CCTACGGGNGCASCAG	560	81
	Pro805-R	CAAGCAGAAGACGGCATACGAGATN NNNNNGTGACTGGAGTTCAGACGT GTGCTCTTCCGATCT- GACTACNVGGGTATCTAATCC		